Open Access

Association of intraoperative transfusion of blood products with mortality in lung transplant recipients

  • Denise Weber1,
  • Silvia R Cottini1,
  • Pascal Locher1,
  • Urs Wenger1,
  • Paul A Stehberger1,
  • Mario Fasshauer1,
  • Reto A Schuepbach1 and
  • Markus Béchir1Email author
Contributed equally
Perioperative Medicine20132:20

DOI: 10.1186/2047-0525-2-20

Received: 7 January 2013

Accepted: 19 September 2013

Published: 27 September 2013

Abstract

Background

The impact of intraoperative transfusion on postoperative mortality in lung transplant recipients is still elusive.

Methods

Univariate and multivariate analysis were performed to investigate the influence of red blood cells (RBCs) and fresh frozen plasma (FFP) on mortality in 134 consecutive lung transplants recipients from September 2003 until December 2008.

Results

Intraoperative transfusion of RBCs and FFP was associated with a significant increase in mortality with odds ratios (ORs) of 1.10 (1.03 to 1.16, P = 0.02) and 1.09 (1.02 to 1.15, P = 0.03), respectively. For more than four intraoperatively transfused RBCs multivariate analysis showed a hazard ratio for mortality of 3.8 (1.40 to 10.31, P = 0.003). Furthermore, non-survivors showed a significant increase in renal replacement therapy (RRT) (36.6% versus 6.9%, P <0.0001), primary graft dysfunction (PGD) (39.3% versus 5.9%, P <0.0001), postoperative need of extracorporeal membrane oxygenation (ECMO) (26.9% versus 3.1%, P = 0.0019), sepsis (24.2% versus 4.0%, P = 0.0004), multiple organ dysfunction syndrome (MODS) (26.9% versus 3.1%, P <0.0001), infections (18.1% versus 0.9%, P = 0.0004), retransplantation (12.1% versus 6.9%, P = 0.039) and readmission to the ICU (33.3% versus 12.8%, P = 0.024).

Conclusions

Intraoperative transfusion is associated with a strong negative influence on outcome in lung transplant recipients.

Keywords

Lung transplantation Mortality Transfusion ICU complications

Background

Liberal transfusion practice has been shown to exert negative influences on morbidity and mortality in different groups of patients due to increased incidence in viral and bacterial infections, activation of inflammatory and coagulation pathways, and immunologic reactions related to transfusion of red blood cells (RBCs) [1]. After lung transplantation the grafts are vulnerable for dysfunction because of denervation, postischemic condition, absent perfusion of bronchial arteries and lacking of lymphatic drainage system. In this context, transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO) are more common than infectious complications, and increase morbidity and mortality [2]. Transfusion of fresh frozen plasma (FFP) may also be associated with adverse effects as transfusion of FFP has been independently associated with a higher risk of developing multiple organ dysfunction syndrome (MODS) and acute respiratory distress syndrome (ARDS) in trauma [3] and critically ill patients [4]. Recently, we demonstrated that intraoperative transfusion of more than 7 units of RBCs in liver transplant recipients was associated with increased mortality [5]. In lung transplant recipients, however, we still lack clear data on the influence of transfusion practice on outcome. To date, there is only one report demonstrating reduced survival after platelet transfusion in lung transplant recipients [6].

The present retrospective study was designed to investigate the influence of intraoperative transfusion of RBCs and FFPs on mortality in lung transplant recipients.

Methods

Following approval by the local Ethics Committee of the Canton of Zurich, Switzerland, (KEK 4), which waived the need for written informed consent for this retrospective analysis, we included a total of 134 consecutive lung transplant recipients who were treated at the ICU, University Hospital of Zurich, Zurich, Switzerland. The study period was 75 months, from September 2003 until December 2008.

Pretransplant recipient data

For baseline characteristics, we collected age, gender, height and weight. The underlying disease and the presence or absence of pulmonary hypertension (PH) was documented. Furthermore, we assessed whether the patients were admitted to transplantation from home, normal ward or an ICU.

Intraoperative data

The number of transfused units of RBCs, FFP, platelet concentrates, fibrinogen and the use of extracorporeal circulation (ECC) during the operation were recorded. The management of coagulation and transfusions practice was done according to internal guidelines. In fact a hemoglobin threshold of 7 g/dL and a coagulation management aiming at functional fibrinogen levels as assessed by thromboelastometry were used [7].

ICU data

The following data were collected: length of stay (LOS) in the ICU, ventilation days, occurrence of renal replacement therapy (RRT) and of primary graft dysfunction (PGD), postoperative use of extracorporeal membrane oxygenation (ECMO), occurrence of sepsis and MODS, frequency of readmission to the ICU, and need of retransplantation. Indications for ECMO were exactly as described previously [8] and for RRT the occurrence of risk, injury, failure, loss, end-stage renal disease (RIFLE) class 2 (injury), as we use routinely in our transplant programme [5, 9].

Analyzing protocol

All of the data were extracted from the patients’ charts. Endpoint of the observational period and for analysis was 31 December 2008. The patients were divided into survivors (S) and non-survivors (NS).

First, baseline and clinical data were analyzed and compared. Then, intraoperative and ICU data were analyzed and compared between the two groups.

Survival was analyzed in terms of ICU mortality and cumulative survival over the entire observation period. In addition, we performed subgroup analyses assessing cumulative survival comparing the patients that received more than four RBCs to the ones with less RBCs transfused. Finally, a multivariate analysis was done to examine whether transfusing RBCs or FFPs are independent risk factors for mortality.

Statistical analysis

Univariate analysis was done with chi-square test for nominal data; unpaired data analysis for continuous variables was performed by means of Mann–Whitney test or logistic regression. For multivariate analysis we used a Cox proportional hazards model to identify independent risk factors for mortality. Calculation of cumulative survival overall and for the subgroups was done by Kaplan–Meier analysis with log rank testing. Data are expressed as mean ± SD; different data expression is stated in the text. All calculations were done with StatView 4.5 (Abacus Concepts, Berkeley, CA, USA). Statistical significance was accepted with P <0.05 (two-sided tests).

Results

Univariate analysis

Baseline characteristics in survivors and non- survivors

Baseline characteristics of the recipients are shown in Table 1. There was no difference in the incidence of PH between survivors and non-survivors (P = 0.16). Concomitant lung disease was similar in all patients, without any statistically significant difference between the two groups (P = 0.65) (Table 2). While 104 patients were admitted from home (82 survivors, 22 non-survivors), 22 were admitted from the normal wards (14 survivors, 8 non-survivors) and 8 patients from the ICU (6 survivors, 2 non-survivors), there was no difference between the two groups (P = 0.41). Mean donor age was 42.5 ± 14.2 years (42.1 ± 14.1 years in the survivors versus 43.8 ± 15.1 years in the non-survivors group, P = 0.57). Taken together, there were no statistically significant differences between survivors and non-survivors.
Table 1

Baseline characteristics

 

All (n = 134)

S (n = 102)

NS (n = 32)

P

Men

79 (78.9%)

58 (56.9%)

21 (65.6%)

0.56

Women

55 (41.9%)

44 (43.1%)

11 (34.4%)

0.56

Age (years)

44.8 ± 16.4 (13 to 68)

44.6 ± 16.7 (13 to 68)

45.8 ± 15.8 (18 to 66)

0.71

Weight (kg)

60.6 ± 16.6 (32 to 122)

59.9 ± 15.2 (32 to 100)

62.8 ± 20.2 (37 to 122)

0.38

Height (m)

1.67 ± 0.90 (1.42 to 1.90)

1.66 ± 0.90 (1.42 to 1.90)

1.69 ± 0.90 (1.55 to 1.88)

0.14

BMI (kg/m2)

21.6 ± 5.0 (14.0 to 39.4)

21.6 ± 5.0 (14.0 to 36.4)

21.8 ± 6.0 (14.5 to 39.4)

0.75

Creatinine (μmol/l)

74 ± 20 (29 to 147)

74 ± 21 (29 to 147)

75 ± 18 (44 to 110)

0.86

PH (pts)

61 (45.5%)

43 (42.1%)

18 (56.2%)

0.16

Data expressed as mean ± SD (range). BMI body mass index, PH pulmonary hypertension, pts patients.

Table 2

Underlying lung diseases

 

All (n = 134)

S (n = 102)

NS (n = 32)

P

CF

47 (35.0%)

38 (37.2%)

9 (28.1%)

 

COPD

25 (18.6%)

19 (18.6%)

6 (18.8%)

 

IPF

27 (20.1%)

19 (18.6%)

8 (25.0%)

 

Alpha-1 deficiency

13 (9.8%)

12 (11.8%)

1 (3.1%)

Chi-squared test for all

Re-TPL

7 (5.3%)

5 (4.9%)

2 (6.3%)

0.65

PPH

6 (4.5%)

3 (2.9%)

3 (9.3%)

 

Sarcoidosis

3 (2.2%)

2 (2.0%)

1 (3.1%)

 

Others

6 (4.5%)

4 (4.0%)

2 (6.3%)

 

Data expressed as absolute numbers (percentage). CF cystic fibrosis, COPD chronic obstructive pulmonary disease, IPF interstitial pulmonary fibrosis, re-TPL retransplantation, PPH primary pulmonary hypertension.

Intraoperative transfusion and use of intraoperative extracorporeal circuit

Intraoperative transfusion of RBCs and FFP was associated with a significant increase in mortality with odds ratios (ORs) of 1.10 (1.03 to 1.16, P = 0.02) and 1.09 (1.02 to 1.15, P = 0.03). There were no statistically significant differences regarding transfusion of platelets (P = 0.48) and application of fibrinogen (P = 0.90). Overall, there was no difference in the use of extracorporeal circuit between the groups (P = 0.31). Details are given in the Tables 3 and 4.
Table 3

Transfusion requirements

 

All (n = 134)

S (n = 102)

NS (n = 32)

P

RBC (U)

5.8 ± 6.2 (0 to 32)

4.8 ± 5.0 (0 to 32)

8.8 ± 8.4 (0 to 29)

0.02

FFP (U)

4.1 ± 6.6 (0 to 30)

3.1 ± 5.2 (0 to 30)

7.2 ± 9.0 (0 to 29)

0.03

Platelets (103/μl)

0.6 ± 1.9 (0 to 16)

0.5 ± 2.1 (0 to 16)

0.8 ± 1.5 (0 to 6)

0.48

Fibrinogen (g)

1.3 ± 2.4 (0 to 12)

1.3 ± 2.4 (0 to 12)

1.4 ± 2.3 (0 to 6)

0.90

Data expressed as mean ± SD (range). RBC red blood cell concentrate, FFP fresh frozen plasma.

Table 4

Intraoperative extracorporeal circuit

 

All

S

NS

P

ECC (pts)

65 (48.5%)

47 (46.0%)

18 (56.2%)

0.31

Data expressed as absolute numbers (percentage). ECC extracorporeal circulation, pts patients.

ICU journey

In non-survivors, LOS in the ICU (P = 0.0007) and ventilation days (P = 0.011) were significantly prolonged compared to survivors. Furthermore, non-survivors had significantly higher incidence of RRT (P <0.0001), PGD (P <0.0001), postoperative ECMO (P = 0.002), sepsis (P <0.0001), MODS (P <0.0001), retransplantation (P = 0.040) and readmission to the ICU (P = 0.024). Details are shown in Table 5.
Table 5

ICU journey

 

All (n = 134)

S (n = 102)

NS (n = 32)

P

LOS ICU (d)

12.9 ± 24.8 (2 to 164)

8.3 ± 10.9 (2 to 62)

27.0 ± 43.8 (2 to 164)

0.0007

LOS hospital (d)

49.2 ± 40.3 (3 to 270)

45.5 ± 29.0 (24 to 238)

60.7 ± 63.1 (3 to 270)

0.075

Ventilation (d)

9.6 ± 24.3 (1 to 162)

5.0 ± 9.1 (1 to 51)

23.9 ± 43.7 (1 to 162)

0.011

CRRT (pts)

14.2% (19)

6.8% (7)

37.5% (12)

<0.0001

PGD (pts)

14.2% (19)

5.9% (6)

40.6% (13)

<0.0001

ECMO (pts)

7.4% (10)

2.9% (3)

21.9% (7)

0.002

Sepsis (pts)

9.0% (12)

4.0% (4)

25.0% (8)

<0.0001

MODS (pts)

11.2% (15)

2.9% (3)

37.5% (12)

<0.0001

Re-TPL (pts)

8.3% (11)

6.8% (7)

12.6% (4)

0.040

Readmission ICU (pts)

17.2% (23)

11.8% (12)

24.4% (11)

0.024

Data expressed as mean ± SD (range) or percentage of incidence (number of patients). CRRT continuous renal replacement therapy, d days, ECMO extracorporeal membrane oxygenation, LOS ICU length of stay in ICU, LOS hospital length of stay in hospital, MODS multiple organ dysfunction syndrome, PGD primary graft dysfunction, pts patients, re-TPL retransplantation.

Mortality rate

Overall ICU mortality was 8.9% (12 out of 134 patients). Overall cumulative 1-year survival was 86% and cumulative 3-year survival was 72.8%. There was a significantly decreased cumulative 1-year survival in the group with transfusion of more than four RBCs (survival 81.2% versus 87.6%, P = 0.042). For details see Figure 1.
Figure 1

Kaplan –Meier analysis with log rank test. There was a significantly lower cumulative 1-year survival in the group with transfusion of more than four RBCs (dashed line). RBC, red blood cell.

Multivariate analysis

Risk factors for mortality

The Cox proportional hazards model for mortality identified transfusion of more than four RBCs (P = 0.003), sepsis in the ICU (P = 0.045), PGD (P = 0.0004) and RRT in the ICU (P = 0.015) as independent risk factors for mortality. In contrast, use of cardiopulmonary bypass intraoperatively (P = 0.35), pre-existing PH (P = 0.36), transfusion of more than five FFPs (P = 0.78), age >60 years (P = 0.10), RRT 6 months after transplantation (P = 0.39), body mass index (BMI) (P = 0.09) and more than 9 days of ventilation in the ICU (P = 0.12) were not discriminated as risk factors for mortality. Details are given in Table 6.
Table 6

Cox proportional hazards model for mortality (n = 134)

Parameter

P

Hazard ratio

CI

Sepsis in ICU

0.045

3.8

1.02 to 14.8

PGD

0.0004

5.4

2.1 to 13.6

Transfusion >4 RBC

0.003

4.7

1.7 to 13.3

CRRT in ICU

0.015

4.0

1.3 to 12.5

>9 ventilation days

0.12

2.2

0.8 to 6.1

BMI >25 kg/m2

0.087

1.07

0.99 to 1.13

Transfusion >5 FFP

0.78

1.14

0.5 to 2.6

Age >60 years

0.10

0.5

0.2 to 1.2

PH

0.36

1.5

0.7 to 3.3

RRT 6 months after TPL

0.39

2.2

0.4 to 13.5

ECC

0.35

0.7

0.3 to 1.6

BMI body mass index, CI confidence interval, CRRT continuous renal replacement therapy, ECC extracorporeal circulation, FFP fresh frozen plasma, PGD primary graft dysfunction, PH pulmonary hypertension, RBC red blood cell, RRT renal replacement therapy, TPL transplantation.

Discussion

The main finding of this study is that intraoperative transfusions of RBCs were associated with increased mortality in lung transplant recipients.

There is a growing body of evidence that the number of intraoperative transfusions alters outcome in different patient populations. Gajic et al. demonstrated that 8% of transfused critically ill patients developed acute lung injury within 6 hours after transfusion [4]. In another study, Christie et al. showed that increased amounts of soluble receptors for advanced glycation end products (a marker for lung epithelial injury) as a consequence of transfusion was clearly associated with PGD in lung transplant recipients [10]. Furthermore, intraoperative transfusion of platelets was associated with worse outcome after lung transplantation [6]. To date, we are still lacking literature regarding the impact of transfusions on long-term outcome in lung transplant recipients. In liver transplant recipients, however, Massicotte et al. prospectively demonstrated that transfusion was associated with worse outcome [11].

Interestingly, in our study population there were no baseline differences between the groups; in particular, there was no influence of underlying diagnosis, intraoperative cardiopulmonary bypass use or pre-existing PH to transfusion rates, which could explain these findings. Nevertheless, we cannot exclude such a difference because of the small sample size, in which the analysis might fail revealing relevant differences between survivors and non-survivors. But, taken together, in this context our study supports the hypothesis that intraoperative transfusion might have negative impact on outcome in lung transplantation recipients. As a consequence, avoiding intraoperative transfusion of at least RBCs as much as feasible might be a beneficial strategy to improve survival in such patients.

A limitation of that suggestion and of this study is clearly the retrospective design. Other limitations are that we did not systematically measure comorbidities in our population and therefore we cannot exclude such an influence on the transfusion requirement. Therefore, a prospective approach in an equal design as Massicotte used in liver transplantation adapted to lung transplants would be important to strengthen or rule out the conclusions drawn from this retrospective setting. Furthermore, the sample size of the study is only moderate and therefore our results must be interpreted very carefully. However, as long as we lack data of a larger sample size or of prospective trials, we recommend being careful with intraoperative transfusion in lung transplantation.

Conclusions

Intraoperative transfusion of RBCs appears to be an independent risk factor for worsened outcome in lung transplant recipients. Therefore, transfusions should be reduced and be avoided as much as possible, at least as long as we lack results of further prospective data.

Notes

Abbreviations

ARDS: 

Acute respiratory distress syndrome

BMI: 

Body mass index

CF: 

Cystic fibrosis

CI: 

Confidence interval

COPD: 

Chronic obstructive pulmonary disease

CRRT: 

Continuous renal replacement therapy

ECC: 

Extracorporeal circulation

ECMO: 

Extracorporeal membrane oxygenation

FFP: 

Fresh frozen plasma

IPF: 

Interstitial pulmonary fibrosis

LOS: 

Length of stay

MODS: 

Multiple organ dysfunction syndrome

OR: 

Odds ratio

PGD: 

Primary graft dysfunction

PH: 

Pulmonary hypertension

PPH: 

Primary pulmonary hypertension

RBC: 

Red blood cell

re-TPL: 

Retransplantation

RIFLE: 

Risk, injury, failure, loss, end-stage renal disease

RRT: 

Renal replacement therapy

TACO: 

Transfusion-associated circulatory overload

TPL: 

Transplantation

TRALI: 

Transfusion-related acute lung injury.

Declarations

Authors’ Affiliations

(1)
Surgical Intensive Care Medicine, University Hospital of Zurich

References

  1. Carson JL, Carless PA, Hebert PC: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012, 4: CD002042PubMed CentralPubMedGoogle Scholar
  2. Kleinman S, Chan P, Robillard P: Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev. 2003, 17 (2): 120-162.View ArticlePubMedGoogle Scholar
  3. Watson GA, Sperry JL, Rosengart MR, Minei JP, Harbrecht BG, Moore EE, Cuschieri J, Maier RV, Billiar TR, Peitzman AB, Inflammation and Host Response to Injury Investigators: Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma. 2009, 67 (2): 221-227. 10.1097/TA.0b013e3181ad5957.View ArticlePubMedGoogle Scholar
  4. Gajic O, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB, O'Byrne MM, Evenson LK, Malinchoc M, DeGoey SR, Afessa B, Hubmayr RD, Moore SB: Transfusion-related acute lung injury in the critically ill: prospective nested case–control study. Am J Respir Crit Care Med. 2007, 176 (9): 886-891. 10.1164/rccm.200702-271OC.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Oberkofler CE, Dutkowski P, Stocker R, Schuepbach RA, Stover JF, Clavien PA, Béchir M: Model of end stage liver disease (MELD) score greater than 23 predicts length of stay in the ICU but not mortality in liver transplant recipients. Crit Care. 2010, 14 (3): R117-10.1186/cc9068.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Zalunardo MP, Thalmann C, Seifert B, D'Cunja J, Weder W, Boehler A, Spahn DR: Impact of preoperative right-ventricular function and platelet transfusion on outcome after lung transplantation. Eur J Cardiothorac Surg. 2011, 39 (4): 538-542. 10.1016/j.ejcts.2010.07.040.View ArticlePubMedGoogle Scholar
  7. Ganter MT, Spahn DR: Perioperative coagulation management. Best Pract Res Clin Anaesthesiol. 2010, 24 (1): 7-8.Google Scholar
  8. Cottini SR, Wenger U, Sailer S, Stehberger PA, Schuepbach RA, Hasenclever P, Wilhelm M, Béchir M: Extracorporeal membrane oxygenation: beneficial strategy for lung transplant recipients. J Extra Corp Technol. 2013, 45 (1): 16-20.Google Scholar
  9. Wenger U, Neff TA, Oberkofler CE, Zimmermann M, Stehberger PA, Scherrer M, Schuepbach RA, Cottini SR, Steiger P, Béchir M: The relationship between preoperative creatinine clearance and outcomes for patients undergoing liver transplantation: a retrospective observational study. BMC Nephrol. 2013, 14: 37-10.1186/1471-2369-14-37.PubMed CentralView ArticlePubMedGoogle Scholar
  10. Christie JD, Shah CV, Kawut SM, Mangalmurti N, Lederer DJ, Sonett JR, Ahya VN, Palmer SM, Wille K, Lama V, Shah PD, Shah A, Weinacker A, Deutschman CS, Kohl BA, Demissie E, Bellamy S, Ware LB, Lung Transplant Outcomes Group: Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med. 2009, 180 (10): 1010-1015. 10.1164/rccm.200901-0118OC.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Massicotte L, Lenis S, Thibeault L, Sassine MP, Seal RF, Roy A: Effect of low central venous pressure and phlebotomy on blood product transfusion requirements during liver transplantations. Liver Transpl. 2006, 12 (1): 117-123. 10.1002/lt.20559.View ArticlePubMedGoogle Scholar

Copyright

© Weber et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement